I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Melasma, an acquired hypermelanosis of the sun-exposed areas of skin, is the most common pigmentary disorder in India.\[[@ref1]\] Its prevalence varies from 0.25% to 4% in Southeast Asia to 1.5%--33.3% in Latin American population.\[[@ref2][@ref3][@ref4]\]

Melasma is presumed to have a multifactorial origin with a complex interplay of genetic predisposition, exposure to ultraviolet radiation and visible light, hormonal imbalance, angiogenesis, and drugs.\[[@ref5]\] Despite the availability of a wide range of therapeutic options, it is difficult to achieve satisfactory response and long-term remission. Hence, the quest for a novel therapeutic molecule is the need of the hour.

Topical depigmenting agents have been the standard of care for the treatment of melasma for a very long time now, and hydroquinone (HQ) has been one of the most extensively studied depigmenting agents. Tranexamic acid (TA) has recently been proposed as an effective alternative in the treatment of melasma. It can be administered through topical, intradermal, and oral routes.\[[@ref6]\]

Though there are no extensive studies conducted on topical TA, the preliminary reports have been promising.\[[@ref7][@ref8][@ref9]\] There is a paucity of data on the efficacy and safety of topical TA in the Indian subcontinent, and this study aimed to evaluate the efficacy of topical 5% TA in melasma and compare it with the gold standard molecule 3% HQ in Indian skin type.

M[ATERIALS AND]{.smallcaps} M[ETHODS]{.smallcaps} {#sec1-2}
=================================================

This was a prospective, single-blind, randomized study conducted for 1.5 years at a tertiary care hospital in Bangalore.

All new cases of melasma more than 18 years of age and previously treated cases of melasma who were off topical and systemic therapy for at least 1 and 3 months, respectively, before the entry into the study were included. Pregnant and nursing women, patients on contraceptive pills, photosensitizing drugs, and those with history of hypersensitivity to HQ or TA, deep venous thrombosis, myocardial infarction, stroke, chronic kidney disease, and defective color vision were excluded.

After obtaining a written informed consent, a detailed history and examination of eligible patients was documented by a single examiner with blinding. Patients were assessed to determine the Fitzpatrick skin type and were examined under Wood's lamp to identify the type of melasma. Baseline investigations such as platelet count, prothrombin time and activated partial thromboplastin time were performed for all the patients to rule out any active coagulation disorder.

They were subjected to simple randomization, allocated into two groups, and administered topical 5% TA solution and 3% HQ cream, respectively, for once daily local application and a sunscreen of SPF 30 for a duration of 12 weeks. Topical 5% TA solution was prepared by diluting TA injection (10%) with sterile water. Digital photographs, Melasma Area Severity Index (MASI), and adverse effects were collated by a single examiner periodically. Subjective improvement was assessed by patient satisfaction score at the end of the study. A repeated measurement analysis of variance, independent *t*-test, Cohen's *d*, and χ^2^ tests were used to analyze data in SPSS 16.0 software. A *P*-value of \<0.05 was considered to be statistically significant.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

A total of 346 patients of melasma were assessed for eligibility. About 120 patients satisfying the aforementioned criteria were included in the study. Final data of 100 patients were analyzed after excluding the patients who were noncompliant and lost to follow-up \[[Figure 1](#F1){ref-type="fig"}\]. The clinicodemographic characteristics of the study subjects are summarized in [Table 1](#T1){ref-type="table"}.

![CONSORT flow diagram of the study](JCAS-12-63-g001){#F1}

###### 

Clinicodemographic characteristics of study subjects

                          **TA group**   **HQ group**
  ----------------------- -------------- --------------
  Age (years)                            
   ≤30                    13 (26)        17 (34)
   31--40                 24 (48)        18 (36)
   41--50                 11 (22)        13 (26)
   \>50                   2 (4)          2 (4)
  Mean age (years)        35.86±7.51     36.32±7.65
  Gender                                 
   Male                   10             6
   Female                 40             44
  Type of melasma                        
   Dermal                 07 (14)        08 (16)
   Epidermal              09 (18)        13 (26)
   Mixed                  34 (68)        29 (58)
  Fitzpatrick skin type                  
   III                    02 (04)        02 (04)
   IV                     26 (52)        24 (48)
   V                      22 (44)        24 (48)

Figures in parentheses indicate percentages.

Majority of the study subjects were less than 40 years of age and had melasma for a duration of 1--3 years. The mean MASI at baseline in TA and HQ groups was 12.39±3.34 and 11.63±3.72, respectively. However, after 12 weeks, mean MASI reduced to 9.47±2.79 and 9.24±3.26 in TA and HQ groups, respectively \[[Figure 2](#F2){ref-type="fig"}\]. Percentage reduction of MASI in TA group was 27% and in HQ group was 26.7%, and the difference in the reduction between the two groups was not statistically significant (*P* \> 0.05).

![Melasma area severity index (MASI) scores within and between tranexamic acid (TA) and hydroquinone (HQ) groups at baseline, and after 4, 8, and 12 weeks](JCAS-12-63-g002){#F2}

A significant decreasing trend was observed in MASI scores at 4, 8, and 12 weeks in both the groups during the study (*P* \< 0.05). There was no difference in terms of onset of action and rapidity of clinical improvement in both the groups. The evaluation of the intervention magnitude at the end of 12 weeks with reference to effect size was considered "large" within the groups, TA group = 0.94 and HQ group = 0.68, but "small" being 0.08 when compared between the groups.

Patients treated with HQ had a significantly higher incidence of adverse effects \[[Table 2](#T2){ref-type="table"}\] and patient satisfaction score was significantly better in TA group (*P* = 0.03) \[[Table 3](#T3){ref-type="table"}; [Figures 3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"}\].

###### 

Comparison of adverse effects between the study groups

  **Treatment group**   **Frequency of adverse effects**   
  --------------------- ---------------------------------- ----------
  TA                    Nil                                3 (6%)
  HQ                    10 (20%)                           09 (18%)
  *P*-value \< 0.05                                        

###### 

Association of patient satisfaction scores with the study groups

  **Patient satisfaction scores**   **TA, *n* (%**)   **HQ, *n* (%**)   **χ**^2^**(*P*-value**)
  --------------------------------- ----------------- ----------------- -------------------------
  Excellent                         02 (4)            00 (0)            12.37 (0.03)\*
  Very good                         08 (16)           11 (22)           
  Good                              30 (60)           17 (34)           
  Satisfactory                      10 (20)           22 (44)           

\*Significant *P*-value.

![Patient on topical TA solution: (A) at baseline and (B) after 12 weeks](JCAS-12-63-g003){#F3}

![Patient on HQ cream: (A) at baseline and (B) after 12 weeks](JCAS-12-63-g004){#F4}

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

Therapy in melasma focuses on sun protection, withdrawal of triggering factors, and reversal of pigmentation. HQ has been regarded as the gold standard in the treatment of melasma for over five decades now. Despite its local adverse reactions, its efficacy has been unquestionable both alone and in combination with other agents.\[[@ref10]\] TA is a well-known antifibrinolytic agent used in menorrhagia. In 1979, Sadako\[[@ref11]\] reported an incidental observation of significant improvement of melasma in patients with chronic urticaria on TA. Ever since its first description, various *in vitro* and *in vivo* studies have been carried out to determine its mechanism of action, efficacy, and adverse effects.

TA inhibits ultraviolet-induced activation of plasminogen by blocking the lysine binding sites on plasminogen and in turn downregulates the activators of melanogenesis.\[[@ref12]\]

Topical TA (2%--5%) in various forms such as cream, gel, emulsion, solution, and mask has been studied in melasma.\[[@ref13]\] Initial report on topical 2% TA emulsion by Kondou *et al.*\[[@ref14]\] in 2007 showed promising results with improvement in 80% of the patients. Split-face trials on TA and HQ have shown significant clinical improvement in melasma compared with baseline, but the difference between the two groups was not statistically significant.\[[@ref8][@ref15]\] A recent randomized study from Tehran comparing 5% TA and 2% HQ in 60 cases of melasma also showed results similar to previous studies indicating that topical TA is as effective as HQ in melasma.\[[@ref9]\]

TA is a novel molecule in the armamentarium of dermatologists for the treatment of melasma. The data on topical TA are limited, and to the best of our knowledge, this is the first randomized trial comparing HQ and topical TA in Indian skin. In our study, MASI in TA and HQ groups at baseline was 12.39+3.34 and 11.63+3.72, respectively. Percentage reduction of MASI in TA and HQ groups at the end of 12 weeks was 27% and 26.7%, respectively. This correlates with the results of two studies from Iran, which showed reduction in MASI with TA but the difference between TA and HQ groups was not statistically significant.\[[@ref8][@ref9]\]

Mild erythema and irritation was observed in 19 of 50 patients in HQ group and it occurred during the beginning of the treatment \[[Figure 5](#F5){ref-type="fig"}\], whereas only 3 of 50 patients of TA group complained of irritation, which subsided on using freshly prepared solution of TA. The occurrence of adverse effects with HQ was significantly higher when compared to TA (*P* \< 0.05) and this could explain better patient satisfaction with TA observed in our study (*P* = 0.03).

![Erythema, telangiectasia, and acneiform eruptions secondary to HQ use: (A) at baseline and (B) after 4 weeks of HQ](JCAS-12-63-g005){#F5}

Topical TA solution is easy to formulate, effective, and safe in the treatment of melasma in Indian skin. However, the limitations in our study include short duration of study and difference in the type of preparations used for comparison. Further large-scale studies are required to find out its ideal concentration, type of vehicle, and frequency of usage, and to evaluate its efficacy in combination with other treatment modalities for long-term benefits.
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